“I am doing everything right.”
“Clean eating. I exercise. I sleep reasonably well. I manage my stress — or I try to. I had my hormones checked and everything came back normal. And yet I still feel like myself wrapped in wet cement. Anxious. Heavy. Exhausted. Like my body is running a program I cannot find or fix.”
She messaged me before our Zoom call. I recognized her immediately — not because I had met her before, but because I have met her dozens of times. In different Zoom windows, different time zones, different life circumstances. She is not one woman. She is many.
And one of the first questions I ask — that most providers never ask — is:
Has anyone looked at your COMT gene?

If you read last week’s blog — One in Five Women Is Wired Differently — you got a preview of what COMT is and why it matters. Today we go deep. Because this single gene variant may be quietly running the show for more women than anyone realizes.
COMT stands for Catechol-O-Methyltransferase. It is the gene that produces the enzyme responsible for breaking down and clearing catecholamines (kat-eh-KOL-ah-meenz — your primary stress hormones, including dopamine, adrenaline, and noradrenaline) — as well as catechol estrogens, the used estrogen metabolites your body must safely clear. [1]
Think of COMT as your body’s drain. When it works well, stress hormones and used estrogens clear efficiently. When COMT is slow — due to a SNP (snip — a single change in your genetic code) — that drain gets sluggish. Things back up. And your hormonal environment shifts in ways your standard labs will never catch.
COMT is not a diagnosis. It is a blueprint. And once you see it, you cannot unsee it.
The most studied COMT variant is called Val158Met. You inherit one copy from each parent — giving you two slow copies (Met/Met), two fast copies (Val/Val), or one of each (heterozygous — HET-er-oh-ZY-gus). [2]
Most of the women I see trend toward slow COMT — so that is where we focus today. But knowing which direction you run changes everything about how we support you.
Your body metabolizes estrogen into metabolites (byproducts of hormone processing). Most are benign. But one group — 4-hydroxy catechol estrogens — are highly reactive and potentially damaging to DNA if not cleared promptly. COMT is their primary clearance mechanism. [3]
When COMT is slow, these reactive estrogen metabolites accumulate — creating oxidative stress (cellular damage from unstable molecules) and raising long-term risk. At the same time, slow COMT means adrenaline and noradrenaline linger after the stress response fires — keeping the nervous system activated and the pregnenolone steal running. [3]
The trifecta I see most often:

Each one makes the others worse. Standard hormone therapy alone rarely resolves it — because the gene was never addressed.
When COMT is already running sluggishly, adding an external load of estrogen-mimicking chemicals — from plastics, pesticides, lawn products, and personal care items — means the clearing system falls even further behind. The backup becomes a flood. [4]
This is why some women react strongly to environments and exposures that others seem to handle without issue. Their COMT is not broken — it is simply overwhelmed. And nobody told them that their personal care products, their cleaning supplies, their Tupperware, their dryer sheets — or the lawn service showing up every Thursday — were part of their hormone story.
If slow COMT is part of your picture, start inside your body and work outward:
I had no idea I had a COMT SNP (“snip” — a genetic variation) until I was 50 years old and tested my DNA. But I had every symptom — exhausted adrenal glands, a flattened cortisol awakening response, a toxic burden that never cleared, and hormone imbalance that standard protocols barely touched. As an HSP, my nervous system was generating a constant catecholamine (stress hormone) load that my slow COMT simply could not keep up with.
Even methylated B12 was not enough. Deeper methylation testing revealed I needed adenocobalamin (ah-den-oh-koh-BAL-ah-min — a specific active form of B12 for complex methylation variants) before things finally began to shift.
When I understood my genetic picture, everything reframed. I was not failing my protocol. My protocol had not yet found me. Supporting my genes with the right nutrient forms, avoiding folic acid entirely, and regulating my nervous system as a daily non-negotiable — that combination is what finally moved the needle.
Not a diagnosis. A direction. The more specific the match, the more worth exploring:

If several of these feel familiar — your COMT gene may be a piece of your puzzle that has never been named.
COMT is not your destiny. It is your starting point:

Your genetics are not a sentence. They are a map. And that map gives you something most women never get: choice.
When you know where your sluggish pathways are, you stop being a passive passenger in your own health. You become the driver. You are not a sitting duck. You never were. You were simply missing information that should have been yours all along.
This is where biohacking truly begins — not with cold plunges and wearables, but with the deepest data point you will ever have: your own DNA.
A reason. A direction. And the power to heal that you never realized was already yours.
For the women who deserve better answers,
Lori Finlay, NP, CNS
Coming Next Month — Gene Series #2
Your Master Detoxifier Is Exhausted
The Glutathione (GSH) gene — why almost every woman I see is running low on the body’s master antioxidant and detoxifier, and what that means for your hormones, your toxin load, and your energy.
Want to Go Deeper?
The COMT pathway connects to other genes — including MTHFR and glutathione — that shape how efficiently your body clears estrogen and stress hormones. I have put together a plain-English breakdown of how they all work together, written so any woman can follow it.
Hit Reply with the words “COMT Deep Dive” and I will send it straight to your inbox.
Note: Citations numbered in order of appearance. APA 7th edition.
1. Männistö, P. T., & Kaakkola, S. (1999). Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacological Reviews, 51(4), 593–628.
2. Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melen, K., Julkunen, I., & Taskinen, J. (1995). Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry, 34(13), 4202–4210.
3. Yager, J. D., & Davidson, N. E. (2006). Estrogen carcinogenesis in breast cancer. New England Journal of Medicine, 354(3), 270–282.
4. Vandenberg, L. N., Colborn, T., Hayes, T. B., Heindel, J. J., Jacobs, D. R., Lee, D. H., & vom Saal, F. S. (2012). Hormones and endocrine-disrupting chemicals: Low-dose effects and nonmonotonic dose responses. Endocrine Reviews, 33(3), 378–455.
5. Brathwaite, J. M., Da Costa, L. A., & El-Sohemy, A. (2011). Catechol-O-methyltransferase genotype is associated with self-reported increased heart rate following caffeine consumption. Journal of Caffeine Research, 1(2), 123–130.
6. Derom, M. L., Sayón-Orea, C., Martínez-Ortega, J. M., & Martínez-González, M. A. (2013). Magnesium and depression: A systematic review. Nutritional Neuroscience, 16(5), 191–206.
7. Stahl, S. M. (2007). L-methylfolate: A vitamin for your monoamines. Journal of Clinical Psychiatry, 68(9), 1352–1353.
8. Bradlow, H. L., Telang, N. T., Sepkovic, D. W., & Osborne, M. P. (1996). 2-hydroxyestrone: The ‘good’ estrogen. Journal of Endocrinology, 150(Suppl), S259–S265.